China breaks the monopoly of foreign patent drugs in the fields of lung cancer and leukemia, and the new drug creation specializes in “bumper harvest”

Xinnuo Medicine 2018-09-28

Lung cancer, leukemia and other fields have broken the monopoly of foreign patent drugs, and the listing of domestic small molecule targeted anticancer drugs has prompted foreign patent drugs to cut prices by more than 50% in China... The major national science and technology achievements are not only 4G mobile communication, Beidou satellite navigation, etc. The hard technology of science and technology, and biotechnology innovations that are closely related to the health of the people.

On the 22nd, the reporter learned at the press conference of the "New Drug Creation National Science and Technology Major Project" held by the Ministry of Science and Technology that China has broken the monopoly of foreign patent drugs in the fields of lung cancer, leukemia, and drug-resistant bacteria prevention and control, and the bio-pharmaceutical industry research and development innovation capability and industry. The development has continued to increase, and the results have been achieved and fruitful.

Qin Huaijin, director of the special implementation management office of the new drug creation and director of the Science and Education Department of the National Health and Family Planning Commission, said that as of the end of the “Twelfth Five-Year Plan”, 90 new varieties of new drug creation projects have been awarded new drug certificates, including hand, foot and mouth disease EV71 vaccine. The first class of new drugs is 5 times of the total before the implementation; the technical transformation of more than 200 kinds of clinically urgently needed varieties, involving 15.3% of the national essential drugs, the quality of the drugs is significantly improved; the domestic small molecule targeted anticancer drug "Eck "Tini" went public, which prompted foreign patented drugs to cut prices by more than 50% in China. For the new outbreak of infectious diseases, it successfully developed emergency drugs such as peramivir and recombinant Ebola virus vaccine, which is a joint prevention of major outbreaks. Joint Control provides technical support and biosecurity.

In addition, lamotrigine was approved by the US FDA, risperidone microsphere injection was approved by the US FDA, and a new drug application was submitted directly. Dioxinxuekang and Danshen Capsules were granted EU listing approval. "China's new drug research and development innovation capabilities have been internationally recognized." Qin Huaijin said.


Drug safety issues have a bearing on the lives and health of the people. There are painful lessons in the world. The non-clinical safety evaluation of drugs is an extremely important part of the necessary stage of new drug research and development. Sang Guowei, the chief technical officer of the new drug creation and academician of the Chinese Academy of Engineering, said that with the special support of new drug creation, China's drug non-clinical safety evaluation platform has achieved a series of major breakthroughs. The pre-clinical safety evaluation of new drugs has been in line with international standards. The key technologies of the platform have reached the international advanced level, which has strongly supported the research and development of new drugs in China and ensured the safety of public drugs.

Hot News

Contact Us

Jinan Xinnuo Pharmaceutical Technology Co., Ltd.

Service hotline: +86- 18615688656 18653156686

E_mail:sales@xinnuopharma.com sabrina@xinnuopharma.com

Send Email

Copyright: Jinan Xinnuo Pharmaceutical Technology Co., Ltd. All rights reserved.   Powered by:MRWL